ArticleBMC cancer2022

Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States.

Arif Hussain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.